Chronic Myeloid Leukemia in Adults
.jpg)
Superior Outcomes for De Novo Blastic Phase CML After Allogeneic Hematopoietic Cell Transplantation
These findings suggest that transplant may improve the prognosis for CML-BP patients even when the disease is advanced.
Despite Advances in CP-CML Treatment, Patients Still Experience Reduced Quality of Life
These investigators found that improvements in CP-CML treatments haven’t been paralleled by similar improvements in quality of life. What needs to be done?
Chronic Myelomonocytic Leukemia Survival: The Care Center Matters
The rare hematologic malignancy known as chronic myelomonocytic leukemia was the subject of a recent study that compared outcomes from patients treated at academic centers versus nonacademic centers. Here’s what the data revealed.
When Chronic Myeloid Leukemia Presents During Pregnancy
Although a rare occurrence, chronic myeloid leukemia is diagnosed in some women during pregnancy, presenting treatment challenges for the clinicians who are charged with their care. Researchers took a closer look.
video
Treatment-Resistant CML: What Options Do We Have?
Akriti Jain, MD, of Cleveland Clinic, discusses how she approaches patients who experience resistance to CML therapy. (0:33)
In CML, What Predicts Degree of Molecular Response With TKIs?
Investigators tracked changes in circulating cytokines, angiogenic factors, and complement components in patients with chronic myeloid leukemia during year 1 of treatment with tyrosine kinase inhibitors in relationship to molecular response.
Can Mutations at Diagnosis in Chronic Myeloid Leukemia Predict Treatment Outcomes?
The gene mutations that drive progression in CML are unclear. A new study found that mutations in activated signaling and myeloid transcription factor genes at diagnosis were associated with worse clinical outcomes after imatinib therapy.
Some Eligible CML Patients Won’t Attempt to Discontinue Their TKI—Why?
While many patients with chronic myeloid leukemia are open to stopping their tyrosine kinase inhibitor, others who are eligible for discontinuation decline the opportunity. What holds them back?
Moving Forward in CML: Efficacy of TKIs in the Elderly
A retrospective analysis reveals that tyrosine kinase inhibitors offer a promising pathway for managing chronic myeloid leukemia in patients ages 75 and older, with increases in major molecular response rates and treatment-free remission.
CML Scoring Systems: Which is the Best Option?
Akriti Jain, MD, of Cleveland Clinic, discusses the evolution of the Sokal risk score, the Euro score, EUTOS, and the ELTS, and how she uses them in practice. (2:29)
Ph+ CML: What’s Different in the United States? And Why?
In Europe, patients with Philadelphia chromosome-positive CML generally have better rates of survival than similar patients in the U.S. These investigators at MD Anderson Cancer Center tried to determine why.
Life Without TKI Therapy: Is It Possible for Patients with CML?
TKI discontinuation could be possible for patients who achieve a deep molecular response, according to an analysis that also projected the possible savings to the U.S. healthcare system.
.jpg)
TKI Use and Vaccinations Reduced Mortality of CML Patients With COVID-19
Using data from the EPICOVIDEHA database, researchers were able to demonstrate that patients with CML had mostly mild infections of COVID-19 and that those receiving vaccinations fared better, in general, than those who did not.
Is It Wise for Patients with CML to Discontinue Their Tyrosine Kinase Inhibitor?
A large, multicenter, retrospective-prospective study shows that, in patients with chronic-phase chronic myeloid leukemia who are eligible for treatment discontinuation, progression is rare and not related to TD.
In Chronic Myeloid Leukemia, Are Patients Setting the Right Course for Themselves?
Researchers asked patients from the U.S. and Italy with newly diagnosed chronic myeloid leukemia to monitor their symptoms and track their adherence to their medications. Are patients following their regimens?
Long-Term Survival After HCT: Which Groups Do Better?
A study from a Florida-based cancer research team took a close look at whether socioeconomic status and race/ethnicity affect survival within approximately 1 year after allogeneic hematopoietic cell transplantation. Here’s what they found.
In CML, Dose Reduction of Tyrosine Kinase Inhibitors May Be Safe
A retrospective study demonstrated that dose reduction—or even discontinuation—of tyrosine kinase inhibitors in patients with chronic myeloid leukemia at risk for treatment-related adverse events may be safe.
video
In Women (and Men) with CML, How to Think About Treatment—or Not—Before, During, and After Pregnancy
In CML, The Importance of Monitoring Cardiovascular Health
Catherine Lai, MD, MPH, of the University of Pennsylvania, discusses the role of regular cardiovascular check-ups in patients taking TKIs. (2:12)
In Patients with CML, Frailty—Not Age—Is a Strong Predictor of Poor Outcomes
Investigators examined the impact of frailty on hospital outcomes in patients with chronic myeloid leukemia, finding frail patients to be at 4 times the risk of in-hospital mortality.
Secondary Hematologic Malignancies on the Rise Following CLL
Utilizing data from SEER, a team of U.S.-based researchers set out to determine the real-world burden of secondary hematologic malignancies in patients with chronic lymphocytic leukemia.
In CML Patients, What Happens When Low-dose TKIs are Discontinued?
TKI dose reduction can be done in CML patients as a way to mitigate adverse events. These investigators went further, conducting a retrospective study to assess the outcome when CML patients discontinued low-dose TKIs.
CML Patients Treated with TKIs have Lower COVID-19 Fatality Rates
Investigators found that patients with CML treated with TKIs had a lower fatality rate when compared with reports in the literature, suggesting future studies of TKIs as a potential COVID-19 treatment are warranted.
Chronic Hematological Malignancies: The Caregivers Face Challenges, Too
Patients with chronic hematological malignancies bear significant physical and emotional pain—and so do their caregivers. Sometimes the strain faced by caregivers impedes the provision of quality care.